Touab Malika, Arumi-Uría Montserrat, Barranco Carlos, Bassols Anna
Departments of Biochemistry and Molecular Biology, School of Veterinary Medicine, Autonomous University of Barcelona, Spain.
Am J Clin Pathol. 2003 Apr;119(4):587-93. doi: 10.1309/ME25-J1G5-ENE5-7LM3.
Nevi with architectural disorder and cytologic atypia of melanocytes (NAD) (also called dysplastic nevi) have been controversial with regard to their relationship with melanoma risk and to their gradation in 3 degrees of atypia. Versican and the melanoma-associated proteoglycan (mel-CSPG) are 2 major proteoglycans expressed by malignant melanoma, and they have a role in the regulation of cell adhesion, migration, and differentiation. We evaluated the differences in versican and mel-CSPG expression in nevi, NAD with several degrees of atypia, and primary malignant melanoma. Immunoreactivity for versican was negative in benign melanocytic nevi, positive in NAD (ranging from weakly to intensely positive), and intensely positive in malignant melanoma. Immunostaining for mel-CSPG was negative in benign melanocytic nevi and mild to moderately positive in NAD and melanoma. Our results suggest that versican expression may be of value for distinguishing NAD from benign melanocytic nevi and for distinguishing severe NAD from mild and moderate NAD.
具有黑素细胞结构紊乱和细胞学异型性的痣（NAD）（也称为发育异常痣）在其与黑色素瘤风险的关系以及其在三个异型性程度上的分级方面一直存在争议。多功能蛋白聚糖和黑色素瘤相关蛋白聚糖（mel-CSPG）是恶性黑色素瘤表达的两种主要蛋白聚糖，它们在细胞黏附、迁移和分化的调节中起作用。我们评估了多功能蛋白聚糖和mel-CSPG在痣、不同异型性程度的NAD以及原发性恶性黑色素瘤中的表达差异。多功能蛋白聚糖的免疫反应性在良性黑素细胞痣中为阴性，在NAD中为阳性（从弱阳性到强阳性），在恶性黑色素瘤中为强阳性。mel-CSPG的免疫染色在良性黑素细胞痣中为阴性，在NAD和黑色素瘤中为轻度至中度阳性。我们的结果表明，多功能蛋白聚糖的表达可能有助于将NAD与良性黑素细胞痣区分开来，并有助于将重度NAD与轻度和中度NAD区分开来。
